Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen - PubMed (original) (raw)

. 1992 May 1;52(9):2563-8.

Affiliations

PMID: 1373671

Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen

L Perey et al. Cancer Res. 1992.

Abstract

The DF3 antigen is a member of a family of high molecular weight glycoproteins aberrantly expressed in malignant mammary epithelium. We have generated a monoclonal antibody (MAb), designated DF3-P, against a recombinant DF3/beta-galactosidase fusion protein. Characterization of this MAb has demonstrated reactivity with immature precursors of DF3 antigen and not with the secreted form. These findings are in contrast to those obtained with MAb DF3, a previously described antibody with predominant reactivity against the mature glycoprotein. The finding that deglycosylation of secreted DF3 antigen with neuraminidase and endo-alpha-N-acetylgalactosaminidase is associated with increased MAb DF3-P reactivity provided additional support for the selectivity of this antibody against the protein core. Epitope mapping studies demonstrate that both the DF3-P and DF3 epitopes are located at a TRPAPGS domain in the 20-amino acid tandem repeat. The results of competition studies with synthetic peptides indicate that the proline in this domain is involved in both epitopes, while the potential glycosylation sites at threonine and serine may contribute to the differential reactivity of MAbs DF3 and DF3-P. Taken together, these findings suggest that both antibodies react with a similar epitope that is modified by the presence of carbohydrate moieties. The results of immunoperoxidase staining studies further demonstrate that while MAb DF3-P reacts with formalin-fixed sections of breast carcinomas, this antibody exhibits little if any reactivity with normal mammary epithelium. Selective expression of the DF3-P epitope in malignant breast cells may be useful in identifying this transformed phenotype.

PubMed Disclaimer

Cited by

MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.
Ren J, Raina D, Chen W, Li G, Huang L, Kufe D. Ren J, et al. Mol Cancer Res. 2006 Nov;4(11):873-83. doi: 10.1158/1541-7786.MCR-06-0204. Mol Cancer Res. 2006. PMID: 17114345 Free PMC article.
Image-guided breast tumor therapy using a small interfering RNA nanodrug.
Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Kumar M, et al. Cancer Res. 2010 Oct 1;70(19):7553-61. doi: 10.1158/0008-5472.CAN-10-2070. Epub 2010 Aug 11. Cancer Res. 2010. PMID: 20702603 Free PMC article.
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Oudejans JJ, Meijer JW, Willemze R, Hilgers J, Meijer CJ. ten Berge RL, et al. J Clin Pathol. 2001 Dec;54(12):933-9. doi: 10.1136/jcp.54.12.933. J Clin Pathol. 2001. PMID: 11729213 Free PMC article.
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging.
Glasgow MD, Chougule MB. Glasgow MD, et al. J Biomed Nanotechnol. 2015 Nov;11(11):1859-98. doi: 10.1166/jbn.2015.2145. J Biomed Nanotechnol. 2015. PMID: 26554150 Free PMC article. Review.
Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression.
Yamashita N, Kufe D. Yamashita N, et al. Int J Mol Sci. 2022 Jul 26;23(15):8219. doi: 10.3390/ijms23158219. Int J Mol Sci. 2022. PMID: 35897789 Free PMC article. Review.

Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen - PubMed (original) (raw)